Editas Medicine, Inc. (EDIT) Stock Price & Analysis
Editas Medicine, Inc. (EDIT) fell 4.76% to USD 2.6 as of July 25, 2026 at 02:21 UTC, according to Nexqual real-time market data.
EDIT last closed at USD 2.73; the session ranged USD 2.59–2.76 on volume of 1,514,524 shares. Market capitalization is $399.00M, with a 52-week range of USD 1.66–4.54 (NMS). Source: Nexqual, July 25, 2026 at 02:21 UTC.
Key Statistics (as of July 25, 2026 at 02:21 UTC)
| Price | USD 2.6 |
|---|---|
| Change | ▼ 4.76% (down) |
| Previous Close | USD 2.73 |
| Open | USD 2.75 |
| Day Range | USD 2.59 – 2.76 |
| 52-Week Range | USD 1.66 – 4.54 |
| Volume | 1,514,524 shares |
| Market Cap | $399.00M |
| Exchange | NMS |
Technical Analysis (EDIT)
Nexqual's technical model rates EDIT "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 02:21 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 35.98 (neutral) |
| vs SMA50 | Below (USD 2.93) |
| MACD | -0.06 (negative) |
Analyst Ratings (EDIT)
Wall Street analysts rate EDIT "None" based on 9 analysts, with a mean price target of USD 5.78 (range USD 1–15), per Nexqual as of July 25, 2026 at 02:21 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 5.78 |
| High Target | USD 15 |
| Low Target | USD 1 |
| Buy / Hold / Sell | 7 / 4 / 2 |
Earnings (EDIT)
| Next Earnings Date | 2026-08-11 |
|---|---|
| EPS Estimate | USD -0.28 |
| Revenue Estimate | $2.75M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.26 vs est -0.24 ▼ miss |
| 2025-12-31 | USD -0.06 vs est -0.21 ▲ beat |
| 2025-09-30 | USD -0.28 vs est -0.38 ▲ beat |
| 2025-06-30 | USD -0.32 vs est -0.38 ▲ beat |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
Financials & Fundamentals (EDIT)
| Total Revenue | $38.69M |
|---|---|
| Revenue Growth (YoY) | -39.20% |
| Gross Margin | -109.24% |
| Operating Margin | -883.19% |
| Profit Margin | -281.59% |
| ROE | -326.07% |
| Debt / Equity | 392.4 |
| Current Ratio | 3.22 |
| Total Cash | $123.65M |
| Total Debt | $17.30M |
| Free Cash Flow | $-73.82M |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
Financial Health Score (EDIT)
Nexqual rates Editas Medicine, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 02:21 UTC.
| Growth | Strong — Revenue +25% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Weak — $124M cash vs $17M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$74M, burning cash |
| Efficiency | Critical — ROE -326%, ROA -26.9% |
Ownership (EDIT)
| Insider Ownership | +0.17% |
|---|---|
| Institutional Ownership | +49.29% |
| Shares Outstanding | 153.46M |
| Float | 79.28M |
| Short % of Float | +14.67% |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
Leadership (EDIT)
Editas Medicine, Inc. is led by Gilmore O'Neill (age 61), President, CEO & Director, per Nexqual as of July 25, 2026 at 02:21 UTC.
| President, CEO & Director | Gilmore O'Neill (age 61) |
|---|---|
| Senior VP & CFO | Amy Parison (age 39) |
| Executive VP & Chief Scientific Officer | Linda C. Burkly (age 68) |
| Vice President of People | Tom Love |
| Senior Vice President of Development and Program Leadership | Brieana Buckley |
Major Backers & Investors (EDIT)
Notable institutional backers of Editas Medicine, Inc. include Renaissance Technologies, JPMorgan, Shaw D.E. & Co., Inc., according to Nexqual as of July 25, 2026 at 02:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Renaissance Technologies | 4.06% |
| JPMorgan | 1.99% |
| Shaw D.E. & Co., Inc. | 1.99% |
| Opaleye Management Inc. | 1.97% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 13.6% |
| BlackRock | 13.49% |
| Geode Capital | 2.36% |
| State Street | 2.12% |
| Nuveen | 2.02% |
| TIAA-CREF Funds-Nuveen Quant Small Cap Equity Fund | 1.71% |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
From Editas Medicine, Inc.'s Latest SEC 10-K Filing (filed 2026-03-09)
Key Strengths & Strategy (as disclosed to the SEC)
- Our Gene Editing Platform We have developed a proprietary gene editing platform that includes different natural and engineered variants of Cas9 and Cas12a.
- In December 2023, we and Vertex Pharmaceuticals Incorporated ("Vertex") entered into a license agreement (the "Vertex License Agreement"), under which Vertex obtained a non-exclusive license for our Cas9 gene editing technology for ex vivo gene editing medicines targeting the BCL11A gene in the fields of SCD and TDT, including Vertex's CASGEVY TM (exagamglogene autotemcel).
- We have developed a proprietary gene editing platform based on CRISPR technology and we continue to expand its capabilities.
- We believe we are the only human gene editing company with a platform that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms of both of these CRISPR systems, and foundational intellectual property for both of these CRISPR systems.
Partnerships
- Examples of these licensing efforts include our non-exclusive license to Vertex for our Cas9 gene editing 11 Table of Co ntents technology for ex vivo gene editing medicines targeting the BCL11A gene in the fields of SCD and TDT, including Vertex's CASGEVY TM (exagamglogene autotemcel); our non-exclusive license to Immatics of our AsCas12a technology to advance gamma-delta T cell therapies for the treatment of cancer; and our collaboration with BMS.
- In connection with the amendment and restatement in November 2019, we entered into a license agreement with BMS (such agreement, the "BMS License Agreement," and together with the BMS Collaboration Agreement, the "BMS Agreements").
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NTLA | Intellia Therapeutics, Inc. | USD 10.73 | ▼ 3.59% |
| CRSP | CRISPR Therapeutics AG | USD 46.54 | ▼ 1.48% |
| BEAM | Beam Therapeutics Inc. | USD 25.1 | ▼ 5.78% |
| PACB | Pacific Biosciences of Californ | USD 1.36 | ▼ 1.45% |
| TWST | Twist Bioscience Corporation | USD 90.27 | ▼ 4.18% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 02:21 UTC. This page is informational and not investment advice.